January 05, 2015

Boehringer Ingelheim Vetmedica, Inc. Receives Pregnant Mare Label Claim for Vetera® Vaccines

USDA Approves Study Data, Making BIVI Vaccines the Only Vaccines on the Market Labeled for Use in Pregnant Mares

Boehringer Ingelheim Vetmedica, Inc. (BIVI) received approval from the United States Department of Agriculture to include “safe for use in pregnant mares” as part of their label claim for their Vetera® vaccine portfolio. This approval allows BIVI to offer the market two vaccine portfolios, VETERA and Calvenza® that have performed safety studies in pregnant mares.

The USDA approved the additional label claim based on safety studies performed in a total of 446 pregnant mares vaccinated twice during each trimester of pregnancy.

The VETERA line of vaccines, which protects against a number of diseases, including equine influenza virus (EIV), has long been a staple within the BIVI line of vaccines. With the introduction of the VETERA XP line in 2013, BIVI is the only company which currently adheres to the current OIE Expert Surveillance Panel on Equine Influenza recommendations by including vaccine strains which offers direct protection against Florida clade 1 and Florida clade 2 equine influenza.

“The approval of this label claim offers veterinarians and horse owners peace of mind in the safety of the VETERA vaccine portfolio when used in pregnant mares,” says Dr. John Tuttle, senior associate director equine professional services, BIVI.

The additional label claim further supports BIVI’s commitment to providing safe and effective vaccines for all horses.

For more information on VETERA XP vaccines, contact Boehringer Ingelheim Vetmedica at 800-325-9167, or visit www.bi-vetmedica.com.

About Boehringer Ingelheim

Boehringer Ingelheim Vetmedica, Inc., (BIVI) is a leader in the animal health industry with its portfolio of innovative vaccine and pharmaceutical solutions for the prevention and treatment of disease within the swine, cattle, equine and pet markets. BIVI is the U.S. division of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other sites in Ames, Fort Dodge and Sioux Center, Iowa.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for the employees and their families and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors of all Boehringer Ingelheim’s endeavors.

With nearly 3,000 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about $1.46 billion (1.07 billion euros) in 2013. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 10% of net sales of the Animal Health business in R&D.

Media Contact

Rene Ward

Director, U.S. Animal Health Communications
3902 Gene Field Road
St. Joseph, Missouri 64506